EMA Approves AI Tool AIM-NASH for Fatty Liver Disease Trials

The European Medicines Agency (EMA) has approved the use of AIM-NASH, an artificial intelligence (AI) tool, in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.

Developed using machine learning, AIM-NASH was trained on over 100,000 biopsy annotations from 59 pathologists, analyzing more than 5,000 liver samples from nine clinical trials. The AI tool is designed to provide consistent and reliable evaluations, reducing variability compared to traditional assessments that rely on multiple pathologists.

With this approval, researchers expect AIM-NASH to improve data accuracy in evaluating new treatments for MASH. Currently, Madrigal Pharmaceuticals’ Rezdiffra is the only U.S.-approved medication for the disease, while Novo Nordisk and Eli Lilly are conducting trials to develop additional treatment options.

The integration of AI into medical research marks a significant step forward, enhancing diagnostic precision and accelerating drug development for complex liver diseases.